Physician profile
Andreas C Pavlides
NPI 1992776637
$43,068.61
in general payments reported to CMS, 2019-2025
41 companies · $1,419 in 2025
The $1,419 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $4,342 · 2021: $4,303 · 2022: $13K · 2023: $5,328 · 2024: $886 · 2025: $1,419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,000 · Food and Beverage: $3,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,000.00 |
| Food and Beverage | $3,632.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $33,816.11 | 2019-2025 | Watchman Access System, Watchman Flx |
| Amgen INC. | $1,031.93 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $880.73 | 2019-2025 | Perclose Prostyle, Thoratec Heartmate 3 Lvas Implant Kit, Navitor |
| Novartis Pharmaceuticals Corporation | $805.77 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $737.09 | 2022-2025 | Optimizer, Optimizer |
| Janssen Pharmaceuticals, INC | $724.63 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $708.78 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $680.93 | 2019-2023 | |
| Esperion Therapeutics, INC. | $503.32 | 2020-2025 | Nexletol |
| Astrazeneca Pharmaceuticals Lp | $407.06 | 2019-2025 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $401.48 | 2023-2025 | Uptravi, Opsumit |
| Pfizer INC. | $283.89 | 2019-2025 | |
| Amarin Pharma, INC. | $235.63 | 2019-2020 | |
| Kowa Pharmaceuticals America, INC. | $216.54 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $199.56 | 2019-2025 | Eliquis, Camzyos |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.55 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $153.64 | 2021-2025 | |
| Biotronik INC. | $132.01 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $121.91 | 2022-2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $108.94 | 2021-2025 | Verquvo |
| W. L. Gore & Associates, INC. | $96.44 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $62.37 | 2019-2023 | Evkeeza |
| Novo Nordisk INC | $54.05 | 2019-2021 | |
| Cvrx, INC. | $52.10 | 2024 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $50.52 | 2024-2025 | Amvuttra, Onpattro |
| Edwards Lifesciences Corporation | $46.47 | 2019-2025 | Sapien 3 Ultra Resilia |
| Daiichi Sankyo INC. | $45.84 | 2023 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $45.65 | 2024 | Arcalyst |
| Scpharmaceuticals INC. | $42.95 | 2025 | |
| Altathera Pharmaceuticals LLC | $38.81 | 2023 | Sotalol Hydrochloride |
| Atricure, INC. | $34.08 | 2023 | |
| Abiomed | $23.37 | 2023 | Impella |
| Cardiva Medical, INC. | $22.06 | 2019 | |
| Inspire Medical Systems, INC. | $17.02 | 2024 | Inspire |
| Azurity Pharmaceuticals, INC. | $16.95 | 2024 | Edarbi |
| Lilly USA, LLC | $16.76 | 2025 | Zepbound, Mounjaro |
| Bridgebio Pharma, INC. | $15.49 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $14.86 | 2025 | Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $13.99 | 2019 | |
| Astellas Pharma US INC | $13.53 | 2019 | |
| Acarix USA INC. | $12.80 | 2024 | Cadscor System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andreas Pavlides listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.